Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MT-201 · 1 trial · 1 indication
Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.
| Arm | Type | Description |
|---|---|---|
| Single Dose of MT-201 and Concomitant Infliximab | EXPERIMENTAL | To evaluate the safety and tolerability of single doses of MT-201 and Concomitant Infliximab |
| Name | Type | Description |
|---|---|---|
| MT-201 | DRUG | MT-201 and Infliximab |
Inclusion Criteria: 1. Male or female (of non-childbearing potential only) between 19 and 55 years of age inclusive, at the time of signing informed consent. 2. Females must be of non-childbearing potential and must have undergone sterilization procedures, and have official documentation, at least ...